A-366
|
|
|
- CAS號:
- 1527503-11-2
- 英文名:
- 5'-Methoxy-6'-[3-(1-pyrrolidinyl)propoxy]spiro[cyclobutane-1,3'-[3H]indol]-2'-amine
- 英文別名:
- A-366;A-336;CS-2077;A-366,MV4;A-366 (A366);A-366; A366;A 366;A-366, 10 mM in DMSO;5'-methoxy-6'-(3-(pyrrolidin-1-yl)propoxy)spiro[cyclobutane-1,3'-indol]-2'-amine;5'-Methoxy-6'-[3-(1-pyrrolidinyl)propoxy]spiro[cyclobutane-1,3'-[3H]indol]-2'-amine;Spiro[cyclobutane-1,3'-[3H]indol]-2'-amine, 5'-methoxy-6'-[3-(1-pyrrolidinyl)propoxy]-
- 中文名:
- A-366
- 中文別名:
- 化合物A366;A-366 (A366);G9A/GLP抑制劑(A-366);A 366,G9A / GLP抑制劑;化合物A366,10 MM DMSO 溶液;5'-甲氧基-6'-(3-(吡咯烷-1-基)丙氧基)螺[環(huán)丁烷-1,3'-吲哚] -2'-胺
- CBNumber:
- CB43038523
- 分子式:
- C19H27N3O2
- 分子量:
- 329.44
- MOL File:
- 1527503-11-2.mol
|
|
|
A-366化學(xué)性質(zhì)
-
沸點:
-
533.6±60.0 °C(Predicted)
-
|
-
密度:
-
1.29±0.1 g/cm3(Predicted)
-
|
-
儲存條件:
-
2-8°C
-
|
-
溶解度:
-
DMSO : 50 mg/mL (151.77 mM; Need ultrasonic)
-
|
-
形態(tài):
-
powder
-
|
-
酸度系數(shù)(pKa):
-
10.18±0.20(Predicted)
-
|
-
顏色:
-
white to beige
-
|
-
InChI:
-
InChI=1S/C19H27N3O2/c1-23-16-12-14-15(21-18(20)19(14)6-4-7-19)13-17(16)24-11-5-10-22-8-2-3-9-22/h12-13H,2-11H2,1H3,(H2,20,21)
-
|
-
InChIKey:
-
BKCDJTRMYWSXMC-UHFFFAOYSA-N
-
|
-
SMILES:
-
C12(C3=C(N=C1N)C=C(OCCCN1CCCC1)C(OC)=C3)CCC2
-
|
A-366性質(zhì)、用途與生產(chǎn)工藝
A-366 是一種高效、高選擇性的肽競爭性組蛋白甲基轉(zhuǎn)移酶 G9a 抑制劑，對 G9a 和 GLP 的 IC50 分別為 3.3 和 38 nM。A-366 比其他 21 種甲基轉(zhuǎn)移酶具有 1000 倍以上的選擇性。A-366 是一種有效的 Spindlin1-H3K4me3 相互作用的抑制劑 (IC50=182.6 nM)。A-366 對人 H3R (Ki=17 nM) 表現(xiàn)出很高的親和力，并且在組胺能和多巴胺能受體家族的亞群間表現(xiàn)出亞型選擇性。
A-366 (0.01-10 μM; 14 days) induces differentiation and affects viability in MV4;11 cells.
A-366 (0.3-3 μM; 72 hours) reduces the total levels of H3K9me2 in a time and concentration dependent manner with a cellular EC50 of ~300 nM in PC-3 prostate adenocarcinoma cells. A-366 (0.01-10 μM; 4 days; HL-60 cells) results in a dose-dependent differentiation and a corresponding decrease in proliferation. DNA content analysis of A-366-treated HL-60 cells showed an accumulation of cells in G1 consistent with cytostasis.
Cell Viability Assay
|
Cell Line:
|
MV4;11 cells
|
|
Concentration:
|
0.01-10 μM
|
|
Incubation Time:
|
14 days
|
|
Result:
|
Resulted in inhibited proliferation and a decrease in viability corresponding to the dose response observed for CD11b staining.
|
A-366 (30 mg/kg; osmotic mini-pump; daily for 14 days) treatment of MV4;11 xenografts elicits growth inhibition.
|
Animal Model:
|
6-8 week old SCID-beige female mice (MV4;11 xenografts)
|
|
Dosage:
|
30 mg/kg
|
|
Administration:
|
By osmotic mini-pump; daily for 14 days
|
|
Result:
|
A modest 45% tumor growth inhibition resulting from A-366 treatment in this model.
|
A-366
上下游產(chǎn)品信息
上游原料
下游產(chǎn)品
| 更新日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS編號 | 包裝 | 價格 |
|---|
| 2026/07/06 | 46807 | A-366, 95%
A-366, 95% | 1527503-11-2 | 100mg | 7916元 |
| 2026/06/05 | HY-12583 | A-366 | 1527503-11-2 | 1 mg | 298元 |
1527503-11-2, A-366 相關(guān)搜索:
- 合成有機(jī)化合物配體
- 細(xì)胞生物學(xué)試劑
- 抑制劑
- A-366 (A366)
- 化合物A366,10 MM DMSO 溶液
- A 366,G9A / GLP抑制劑
- 5'-甲氧基-6'-(3-(吡咯烷-1-基)丙氧基)螺[環(huán)丁烷-1,3'-吲哚] -2'-胺
- 化合物A366
- G9A/GLP抑制劑(A-366)
- 1527503-11-2
- A-366
- A-366 (A366)
- A-366, 10 mM in DMSO
- A-366,MV4
- 11,selective,cells,peptide-competitive,epigenetics,Inhibitor,interaction,inhibit,H3K4me3,Epigenetic Reader Domain,leukemia,Histone Methyltransferase,methyltransferase
- Spiro[cyclobutane-1,3'-[3H]indol]-2'-amine, 5'-methoxy-6'-[3-(1-pyrrolidinyl)propoxy]-
- 5'-methoxy-6'-(3-(pyrrolidin-1-yl)propoxy)spiro[cyclobutane-1,3'-indol]-2'-amine
- A-366; A366;A 366
- CS-2077
- A-336
- 5'-Methoxy-6'-[3-(1-pyrrolidinyl)propoxy]spiro[cyclobutane-1,3'-[3H]indol]-2'-amine